(Q41578456)

4 October 2017

Therapeutic potential of interleukin-27 against cancers in preclinical mouse models (English)

1 reference

4 October 2017

Izuru Mizoguchi

1

1 reference

4 October 2017

Yukino Chiba

2

1 reference

4 October 2017

Jun-Ichi Furusawa

3

1 reference

4 October 2017

Mingli Xu

4

1 reference

4 October 2017

Ren Tsunoda

5

1 reference

4 October 2017

Kaname Higuchi

6

1 reference

4 October 2017

Takayuki Yoshimoto

7

1 reference

4 October 2017

27 May 2015

1 reference

4 October 2017

1 reference

4 October 2017

4

1 reference

4 October 2017

10

1 reference

4 October 2017

e1042200

1 reference

Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer

4 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

Interleukin-27 signaling promotes immunity against endogenously arising murine tumors

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

Antiangiogenic and antitumor activities of IL-27.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

Potent antitumor activity of interleukin-27.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589049

A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26451308

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/2162402X.2015.1042200

1 reference

4 October 2017

1 reference

4 October 2017

PubMed publication ID

26451308

1 reference